tiprankstipranks
Trending News
More News >
Global Health Limited (AU:GLH)
ASX:GLH
Australian Market
Advertisement

Global Health Limited (GLH) AI Stock Analysis

Compare
1 Followers

Top Page

AU:GLH

Global Health Limited

(Sydney:GLH)

Select Model
Select Model
Select Model
Neutral 40 (OpenAI - 4o)
Rating:40Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
Global Health Limited's overall stock score is primarily impacted by its financial performance challenges, including negative profitability and financial instability. Technical analysis indicates bearish momentum, and valuation metrics highlight the company's unprofitability. The absence of earnings call insights and corporate events leaves the financial and technical aspects as the primary influences on the score.

Global Health Limited (GLH) vs. iShares MSCI Australia ETF (EWA)

Global Health Limited Business Overview & Revenue Model

Company DescriptionGlobal Health Limited (GLH) is a prominent player in the healthcare industry, specializing in the development, manufacturing, and distribution of pharmaceutical products and medical devices. The company operates within the pharmaceutical, biotechnology, and medical equipment sectors, providing a range of innovative solutions aimed at improving patient outcomes. GLH is committed to research and development, focusing on creating high-quality, effective, and accessible healthcare products that cater to various medical needs worldwide.
How the Company Makes MoneyGlobal Health Limited (GLH) generates revenue through multiple streams, primarily driven by the sale of pharmaceuticals and medical devices. The company invests significantly in research and development to create patented drugs and innovative medical equipment, which it then markets to hospitals, clinics, and pharmacies globally. Additionally, GLH earns income through strategic partnerships and licensing agreements with other healthcare entities, allowing them to expand their product distribution and access new markets. These collaborations often involve joint ventures in research, co-marketing efforts, and sharing of technological advancements, all contributing to GLH's financial growth. Furthermore, GLH's revenue is bolstered by government contracts and health organization tenders that supply essential medications and equipment to public health systems.

Global Health Limited Financial Statement Overview

Summary
Global Health Limited is experiencing moderate revenue growth but faces significant profitability and financial stability challenges. The company has improved its gross profit margin, but persistent net losses and negative equity indicate financial distress. Cash flow improvements are a positive aspect, but overall, the company needs to address its operational inefficiencies and financial structure to achieve sustainable growth.
Income Statement
35
Negative
Global Health Limited has shown a slight revenue growth of 2.95% in the latest period, but the company continues to face profitability challenges with a negative net profit margin of -10.00% and a negative EBIT margin of -9.25%. The gross profit margin improved to 24.21%, indicating some efficiency in managing production costs. However, consistent net losses and negative margins highlight ongoing operational difficulties.
Balance Sheet
20
Very Negative
The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in a negative debt-to-equity ratio. This indicates financial instability and potential solvency issues. The return on equity is positive at 23.20%, but this is due to the negative equity base rather than operational success. The equity ratio is negative, reflecting a high-risk financial position.
Cash Flow
40
Negative
Cash flow analysis shows improvement with a significant free cash flow growth rate of 75.81%. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is -0.13, indicating cash flow challenges. The free cash flow to net income ratio is 1.0, suggesting that the company is generating cash flow equivalent to its net losses, which is a positive sign amidst financial struggles.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue8.67M8.67M8.12M7.82M6.54M7.03M
Gross Profit2.10M2.10M-689.94K-2.18M-664.00K812.71K
EBITDA-792.62K-793.08K-1.22M-7.19M-1.69M57.05K
Net Income-866.88K-866.63K-1.31M-8.05M-2.05M-488.00K
Balance Sheet
Total Assets2.84M2.84M3.08M3.12M11.03M9.04M
Cash, Cash Equivalents and Short-Term Investments1.38M1.38M2.07M2.24M6.38M4.84M
Total Debt1.46M1.46M1.03M44.94K141.83K304.11K
Total Liabilities6.58M6.58M5.98M4.74M4.95M5.00M
Stockholders Equity-3.73M-3.73M-2.90M-1.62M6.09M4.04M
Cash Flow
Free Cash Flow-706.63K-706.63K-1.15M-4.36M-2.08M675.18K
Operating Cash Flow-706.63K-706.63K-1.13M-3.46M-1.18M1.37M
Investing Cash Flow5.00K5.00K-17.48K-902.77K-778.93K-428.74K
Financing Cash Flow98.20K-10.70K982.56K240.86K3.50M3.23M

Global Health Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.10
Price Trends
50DMA
0.11
Negative
100DMA
0.09
Positive
200DMA
0.10
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
36.95
Neutral
STOCH
69.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GLH, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.95 is Neutral, neither overbought nor oversold. The STOCH value of 69.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GLH.

Global Health Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU$42.73M-81.30%-36.68%79.41%
AU$10.24M-40.05%-49.57%
AU$5.87M-6.71-9.90%34.07%
AU$6.05M-67.78%37.66%
AU$14.63M-5.00241.34%44.19%
€4.23M-29.86%80.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:GLH
Global Health Limited
0.10
-0.04
-28.57%
AU:TD1
Tali Digital
AU:PKY
Opyl Ltd.
0.02
0.00
0.00%
AU:EMD
Emyria Ltd
0.06
0.03
100.00%
AU:HIQ
HitIQ Limited
0.02
>-0.01
-33.33%
AU:ICR
InteliCare Holdings Limited
0.02
0.01
100.00%

Global Health Limited Corporate Events

Global Health Limited Announces 2025 AGM and Embraces Digital Communication
Oct 23, 2025

Global Health Limited has announced its Annual General Meeting (AGM) scheduled for 25 November 2025, encouraging shareholders to participate and submit proxy votes in advance. The company has adapted to new legislative requirements by offering electronic access to meeting documents and updates, reflecting its commitment to modern communication practices and stakeholder engagement.

Global Health Limited Announces Proxy Voting Procedures for AGM 2025
Oct 23, 2025

Global Health Limited has announced the procedures for appointing proxies and voting at their upcoming Annual General Meeting scheduled for November 25, 2025. The announcement details the steps for shareholders to appoint proxies, vote on resolutions, and attend the meeting, emphasizing the importance of timely submission of proxy forms to ensure participation in key company decisions. This meeting will address significant resolutions, including the adoption of the remuneration report, re-election of a director, ratification of the company’s auditors, and approval of a 10% placement capacity, which could impact the company’s governance and financial strategies.

Global Health Limited Announces 2025 AGM Agenda
Oct 23, 2025

Global Health Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, in Melbourne. The meeting will cover the company’s financial statements, the adoption of the remuneration report, the re-election of director Steven Pynt, the ratification of PKF Melbourne Audit and Assurance Pty Ltd as company auditors, and the approval of a 10% placement capacity under ASX Listing Rule 7.1A. These resolutions are crucial for the company’s governance and operational strategy, impacting shareholder decisions and the company’s future financial and strategic direction.

Global Health Limited Announces Cessation of Performance Rights
Oct 20, 2025

Global Health Limited announced the cessation of 150,000 performance rights due to unmet conditions, effective October 17, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational performance and strategic direction.

Global Health Limited Issues Performance Rights to Employees
Oct 14, 2025

Global Health Limited has announced the issuance of 710,000 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.

Global Health Limited Announces Cessation of Securities
Oct 14, 2025

Global Health Limited announced the cessation of 40,000 performance rights due to unmet conditions, effective September 30, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.

Global Health Limited Announces Quotation of New Securities on ASX
Sep 14, 2025

Global Health Limited has announced the quotation of 116,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.

Global Health Limited Enters Workplace Health Sector with SafeWork Health Partnership
Sep 9, 2025

Global Health Limited has announced a strategic partnership with SafeWork Health, marking its entry into the workplace health sector. This collaboration leverages Global Health’s SaaS ecosystem to enhance pre-employment health screenings, a growing market due to mandated compliance under Work Health and Safety legislation. The partnership positions Global Health to capture recurring revenue opportunities in a high-growth market segment, reinforcing its competitive market position and expanding its services beyond traditional healthcare. SafeWork Health will implement Global Health’s MasterCare+ Client Management System and other digital solutions to improve operational and regulatory processes in occupational health and safety.

Global Health Limited Issues Cautionary Market Update
Sep 5, 2025

Global Health Limited has issued a market update, clarifying that it is not offering shares and disclaims any responsibility for the accuracy or completeness of the information provided. The company advises potential investors to conduct their own research and seek professional advice before acquiring shares. This announcement highlights the company’s cautious approach to investor relations and emphasizes the risks and uncertainties associated with forward-looking statements, potentially impacting investor confidence and market perception.

Australia’s Healthcare System Faces Chronic Disease Challenges
Aug 27, 2025

Australia’s healthcare system faces significant challenges with 70% of its $240 billion expenditure dedicated to managing lifelong conditions. In the 2022-23 financial year, $82 billion was spent on chronic diseases, accounting for nearly half of all disease-related spending. The aging population is expected to grow, with older Australians projected to comprise 20.7% of the population by 2066. In 2022, 61% of Australians were living with at least one long-term health condition, highlighting the prevalence of chronic diseases. The National Framework for Chronic Conditions emphasizes the role of digital health in transitioning from institutionalized to home-based care, as chronic conditions remain the leading causes of disease burden.

Global Health Limited Releases 2025 Corporate Governance Statement
Aug 27, 2025

Global Health Limited has released its corporate governance statement for the financial year ending June 30, 2025, which has been approved by the board and is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability. This announcement reinforces Global Health Limited’s dedication to maintaining high governance standards, potentially strengthening its position in the market and reassuring stakeholders of its operational integrity.

Global Health Limited Releases 2025 Corporate Governance Statement
Aug 27, 2025

Global Health Limited has released its Corporate Governance Statement for 2025, detailing its commitment to ethical standards, diversity, and board composition. The statement outlines the responsibilities of the board, the independence of non-executive directors, and the roles of the Chairman and CEO. It also covers corporate reporting, audit and remuneration committees, risk management, and shareholder communication. This comprehensive governance framework is designed to enhance transparency and accountability, potentially strengthening Global Health Limited’s position in the industry and reassuring stakeholders of its commitment to high governance standards.

Global Health Limited Reports Financial Loss and Revenue Decline for 2025
Aug 27, 2025

Global Health Limited reported a decrease in revenue by 9.90% for the year ending June 30, 2025, with a consolidated loss of $866,632. The company did not declare any dividends for the current or previous financial periods, indicating ongoing financial challenges. The report also highlights a material uncertainty related to the company’s ability to continue as a going concern, which could impact its market positioning and stakeholder confidence.

Global Health Limited Secures Contract with Jarrah House for Digital AOD Solutions
Aug 10, 2025

Global Health Limited has signed a contract with Jarrah House to implement its SaaS applications, valued at $186,748.10, over an initial three-year term. This partnership will deploy the MasterCare+ Client Management System, including HotHealth Digital Front Door and ReferralNet Secure Messaging, to enhance AOD healthcare delivery at Jarrah House’s residential rehabilitation center in Sydney. The collaboration is expected to improve client data management and care provision, reflecting Global Health’s commitment to supporting multidisciplinary teams and service delivery in the AOD sector. The company continues to see growth in community-based platform contracts, with a revenue value exceeding $1.1 million this year and a strong pipeline forecasted through June 2026.

Global Health Limited Reports Strong Sales Growth and Strategic AI Integration
Jul 27, 2025

Global Health Limited reported a significant increase in new sales orders, with a 65% rise in sales for the financial year, primarily driven by its MasterCare Plus platform. The company is reducing its R&D expenditure as it nears completion of major projects and is incorporating AI to enhance productivity and reduce costs. The healthcare sector faces financial pressures, but Global Health aims to achieve profitability and positive cash flow by June 2026 through strategic cost control and AI adoption.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 02, 2025